Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-11-14 |
2022-09 |
-0.54 |
N/A |
N/A |
N/A |
2022-08-08 |
2022-06 |
-0.52 |
N/A |
N/A |
N/A |
2022-05-10 |
2022-03 |
-0.64 |
N/A |
N/A |
N/A |
2022-03-29 |
2021-12 |
-0.71 |
N/A |
N/A |
N/A |
2021-11-08 |
2021-09 |
-0.7 |
N/A |
N/A |
N/A |
2021-08-09 |
2021-06 |
-0.72 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-10-25 |
JP Morgan |
Downgrade |
Neutral |
Underweight |
2022-10-25 |
Needham |
Downgrade |
Buy |
Hold |
2022-10-24 |
Cowen & Co. |
Downgrade |
Outperform |
Market Perform |
2022-05-24 |
Goldman Sachs |
Upgrade |
|
Buy |
2022-05-11 |
Goldman Sachs |
Upgrade |
|
Buy |
2022-04-13 |
Goldman Sachs |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-11-22 |
ALPERN ROBERT J |
Director |
0.00 |
Sale |
2022-11-24 |
BONITA DAVID P |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2021-12-19 |
COUFAL SANDRA I |
Director and Beneficial Owner of more than 10% of a Class of Security |
6.53M |
Sale |
2021-06-09 |
FALBERG KATHRYN E. |
Director |
59.16K |
Stock Award(Grant) |
2022-10-12 |
ISERN BRIAN M |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2021-12-07 |
KLAERNER GERRIT |
Chief Executive Officer |
395.48K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Orbimed Advisors LLC. |
10.28M |
1.11M |
18.47% |
2022-09-29 |
VR Adviser, LLC |
9.05M |
977.41K |
16.26% |
2022-09-29 |
Blackrock Inc. |
3.70M |
399.43K |
6.64% |
2022-09-29 |
Frazier Life Sciences Management, L.P. |
2.55M |
275.36K |
4.58% |
2022-09-29 |
Commodore Capital, LP |
1.98M |
213.34K |
3.55% |
2022-09-29 |
Vanguard Group, Inc. (The) |
1.66M |
179.48K |
2.99% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Vanguard Total Stock Market Index Fund |
1.02M |
110.31K |
1.83% |
2022-09-29 |
Vanguard Extended Market Index Fund |
330.28K |
35.67K |
0.59% |
2022-12-30 |
iShares Russell 2000 Value ETF |
281.99K |
30.45K |
0.51% |
2022-10-30 |
Fidelity Small Cap Index Fund |
261.69K |
28.26K |
0.47% |
2022-12-30 |
iShares Russell 3000 ETF |
232.16K |
25.07K |
0.42% |
2022-10-30 |
Goldman Sachs Small Cap Value Insights Fund |
143.68K |
15.52K |
0.26% |